Evidence map›Paper›PMID 36894313›Full record

ArticleJournal of clinical pathology2023

Identification of a protein expression signature distinguishing early from organising diffuse alveolar damage in COVID-19 patients.

Helen Ashwin, Luke Milross, Julie Wilson, Joaquim Majo, Jimmy Tsz Hang Lee, Grant Calder, Bethany Hunter, Sally James, Dimitris Lagos, Nathalie Signoret and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Helen Ashwin *York Biomedical Research Institute, Hull York Medical School, University of York, York, UK.
Luke Milross *Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Julie Wilson *Department of Mathematics, University of York, York, UK.
Joaquim MajoDepartment of Cellular Pathology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Jimmy Tsz Hang LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Grant CalderBiosciences Technology Facility, University of York, York, UK.
Bethany HunterNewcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Sally JamesBiosciences Technology Facility, University of York, York, UK.
Dimitris LagosYork Biomedical Research Institute, Hull York Medical School, University of York, York, UK.
Nathalie SignoretYork Biomedical Research Institute, Hull York Medical School, University of York, York, UK.
Andrew FilbyBiosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Omer Ali BayraktarWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Andrew J FisherNewcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK paul.kaye@york.ac.uk a.j.fisher@newcastle.ac.uk.
Paul M KayeYork Biomedical Research Institute, Hull York Medical School, University of York, York, UK paul.kaye@york.ac.uk a.j.fisher@newcastle.ac.uk.ORCID http://orcid.org/0000-0002-8796-4755
University of York · GBNewcastle University · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBWellcome Sanger Institute · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Diffuse alveolar damage (DAD) is the histological expression of acute respiratory distress syndrome and characterises lung pathology due to infection with SARS-CoV-2, and other respiratory pathogens of clinical significance. DAD reflects a time-dependent immunopathological process, progressing from an early/exudative stage through to an organising/fibrotic stage, yet within an individual these different stages of DAD may coexist. Understanding the progression of DAD is central to the development of new therapeutics to limit progressive lung damage. Here, we applied highly multiplexed spatial protein profiling to autopsy lung tissues derived from 27 patients who died from COVID-19 and identified a protein signature (ARG1, CD127, GZMB, IDO1, Ki67, phospho-PRAS40 (T246) and VISTA) that distinguishes early DAD from late DAD with good predictive accuracy. These proteins warrant further investigation as potential regulators of DAD progression.

Indexed as

COVID-19Respiratory Distress SyndromeAutopsyHumansLungSARS-CoV-2COVID-19Immune System DiseasesINFLAMMATIONLUNG

Identifiers

PMID36894313
PMCPMC10423525
OpenAlexW4323659810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.